NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

基於 CRISPR 的治療藥物市場

CRISPR Based Therapeutics Market by Type of Therapy (CAR-T Therapy, Hematopoietic Stem Cell Therapy, T cell Therapy and TIL), Therapeutic Approach (In vivo, Ex vivo), Therapeutic Area (Oncological Disorders,

出版商 Roots Analysis 商品編碼 1024364
出版日期 內容資訊 英文 217 Pages
商品交期: 最快1-2個工作天內
價格
基於 CRISPR 的治療藥物市場 CRISPR Based Therapeutics Market by Type of Therapy (CAR-T Therapy, Hematopoietic Stem Cell Therapy, T cell Therapy and TIL), Therapeutic Approach (In vivo, Ex vivo), Therapeutic Area (Oncological Disorders,
出版日期: 2021年06月30日內容資訊: 英文 217 Pages
簡介

CRISPR 是一個 DNA 序列家族,它們構成了負責保護原核細胞免受噬菌體感染的原始免疫系統。它於 1987 年首次被報導,但直到 2012 年才認識到其作為基因編輯工具的潛力。從那時起,CRISPR 革命沒有顯示出放緩的跡象,並在分子生物學和治療藥物開發方面取得了長足的進步。

目前,基於 CRISPR 的療法的臨床試驗主要針對癌症和血液疾病。然而,一些候選產品正在研究特定的神經和傳染病,尤其是複發性疾病。自 2014 年以來,對該技術的整體興趣呈指數級增長,有幾家初創公司進入市場,前 10 名製藥公司中有 6 家在此方向上重組了他們的努力。

本報告調查和分析了全球基於 CRISPR 的療法市場,並提供了有關當前市場狀況和未來機會的系統信息。

目錄

第一章前言

第 2 章執行摘要

第 3 章介紹

第 4 章市場概覽

  • 章節概述
  • 基於 CRISPR/Cas 的療法:臨床管道
  • 基於 CRISPR/Cas 的療法:已註冊的臨床試驗
  • 基於 CRISPR 的療法:藥物發現和臨床前管道
  • 基於 CRISPR/Cas 的療法:開發者情況

第五章公司簡介

  • 章節概述
  • CRISPR 療法
  • Editas 醫學
  • Intellia Therapeutics
  • 切除生物治療
  • Locus Biosciences
  • 石墨生物
  • Emendo Biotherapeutics(AnGes 的子公司)
  • 光束療法
  • Modalis 療法
  • 避難所生物技術

第六章專利分析

  • 章節概述
  • 範圍和方法
  • CRISPR/Cas基因編輯技術:專利分析
  • CRISPR/Cas基因編輯技術:專利對標
  • CRISPR/Cas基因編輯技術:專利評估分析
  • 熱門專利:按引用次數分析

第 7 章夥伴關係和協作

  • 章節概述
  • 合作模式
  • CRISPR 許可情況:代理許可
  • 基於 CRISPR/Cas 的療法:最近的合作夥伴關係

第八章融資與投資分析

  • 章節概述
  • 資金類型示例
  • 基於 CRISPR/Cas 的療法和相關技術:最近的資助示例
  • 結論

第9章創業健康指數

  • 章節概述
  • 一家專注於 CRISPR/Cas 療法的初創公司
  • 啟動基準測試

第10章市場規模和機會分析

  • 章節概述
  • 範圍和限制
  • 主要前提和預測方法
  • 基於 CRISPR/Cas 的整體治療藥物市場
  • 基於 CRISPR/Cas 的治療藥物市場:按治療藥物類型分佈
  • CRISPR/基於 Cas 的治療市場:按治療方法分佈
  • 基於 CRISPR/Cas 的治療藥物市場:按治療領域分佈
  • CRISPR/Cas 療法市場:區域分佈
  • 按產品的銷售預測

第11章執行考慮

第12章結論

第十三章附錄1:表格數據

第 14 章附錄 2:公司/組織名單

目錄

Title:
CRISPR Based Therapeutics Market
by Type of Therapy (CAR-T Therapy, Hematopoietic Stem Cell Therapy, T cell Therapy and TIL), Therapeutic Approach (In vivo, Ex vivo), Therapeutic Area (Oncological Disorders, Hematological Disorders, Ophthalmic Diseases and Infectious Disease), and Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2021-2030.

Overview:

Clustered regularly interspaced short palindromic repeats (CRISPR) are a family of DNA sequences, which constitute a primitive immune system that is responsible for protecting prokaryotic cells from phage infections. It was first described in 1987, however, its potential as a gene editing tool was not realized until 2012. Since then, the CRISPR revolution has not shown any signs of slowing down and has been responsible for significant advances in molecular biology and therapy development. Fundamentally, the CRISPR/Cas system involves specific palindromic DNA sequences which work in tandem with a family of caspase enzymes (Cas9, Cas12), in order to excise gene fragments with high precision. Compared to the other targeted nuclease-based systems, CRISPR is relatively faster, and cost-efficient; as a result, the demand for this gene editing tool is very high. The relatively recent discovery / development of novel accompanying nucleases, namely Cas12a, Cas13, Cas14 and dCas9, has significantly improved the precision of this technology. Presently, there are several companies using different variants of the CRISPR/Cas technology for basic research, and the development of gene editing solutions. However, the therapeutic use of this versatile genetic manipulation tool is only being investigated by a select few stakeholders in the pharmaceutical industry. The aforementioned scenario is attributed to the surrogate licensing model, which has granted exclusive control of the associated intellectual property (IP) to three leading players, namely Editas Medicine, CRISPR Therapeutics and Intellia Therapeutics, in the contemporary market.

Clinical trials of CRISPR based therapeutics are currently focused mainly on oncological and hematological disorders; however, several product candidates against certain neurological disorders and infectious diseases, specifically targeting recurrent conditions, are under investigation. Post 2014, the overall interest in this technology has grown exponentially, with several start-ups entering the market and 6 of the top 10 pharmaceutical companies restructuring their efforts in this direction. Over time, a substantial body of evidence has also been generated validating the therapeutic applications of this technology, which has, in turn, prompted the establishment of numerous strategic partnerships (focused on therapy development and clinical research) and has caused investors to put in significant capital into innovator companies involved in this domain, over the last two years alone. In fact, the three leading companies in this industry segment together have combined market capitalization of more than USD 10 billion, and have raised more than USD 2.8 billion in various funding rounds. Despite the possibly limitless potential of the CRISPR/Cas technology, further investigation, probing its safety and therapeutic efficacy in large diverse populations, is required. Key impediments to approval and other existing challenges that are being addressed by stakeholders, include off-target toxicity-related concerns and complexities related to the delivery of CRISPR components into target cells. Concerning delivery, innovators in this field have reported notable success using different types of platforms for facilitating the intracellular administration of CRISPR components; examples of successful delivery methods include electroporation, AAV vectors and lipid nanoparticles (LNPs). A few companies are also evaluating bacteriophages as a potential delivery system for such products. Promising clinical results, and ongoing technical developments, coupled to the growing interest of biopharmaceutical developers, are anticipated to push pipeline products to higher phases and on to commercialization. We believe that the market is likely to evolve at a commendable pace over the next decade.

Scope of the Report:

The "CRISPR Based Therapeutics Market, 2021-2030" report features an extensive study of the current market landscape and future opportunity for the players involved in the development of CRISPR based therapeutics for the treatment of a variety of disease conditions. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies. Amongst other elements, the report includes:

  • A review of the CRISPR based therapeutics that are currently in different stages of development. It features a detailed analysis of pipeline molecules, based on several relevant parameters, such as target therapeutic area (autoimmune disorders, cardiovascular disorders, dermatological disorders, genetic disorders, hematological disorders, immunological disorders, infectious diseases, inflammatory disorders, metabolic disorders, muscular diseases, neurological disorders, oncological disorders, ophthalmic diseases and others), phase of development (discovery, preclinical and clinical), approach of therapy (ex vivo and in vivo) , cell source (autologous and allogeneic), type of therapy (CAR-T therapy, HSC therapy, T cell therapy, Phage therapy and others), and the type of technology used. It also includes information on the completed, ongoing and planned clinical trials for CRISPR based therapeutics, sponsored by various industry players.
  • Elaborate profiles of key players in this domain. Each company profile features a brief overview of the company, its financial information (if available), a brief description of its therapeutic candidates, recent developments, and an informed future outlook.
  • An in-depth analysis of around 2,000 patents related to CRISPR technology that have been filed / granted, since 2015, highlighting the key trends associated with these patents, across type of patent, publication year and application year, regional applicability, IPCR symbols, emerging focus areas, inventor information, leading patent assignees (in terms of number of patents filed / granted), patent benchmarking and valuation.
  • An analysis of the partnerships that have been inked by various stakeholders engaged in the development of CRISPR based therapeutics, during the period 2014-2020, covering research and licensing agreements, R&D agreements, licensing agreements, licensing and manufacturing agreement, product development and manufacturing agreements, joint ventures and other types of partnership deals.
  • An analysis of the investments made at various stages of development of the companies engaged in this field, covering instances of seed financing, venture capital financing, grants / awards, capital raised from IPOs and subsequent offerings.
  • An analysis of the start-ups (established in the time period between 2013-2020 and have less than 200 employees) engaged in the development of CRISPR based therapeutics, based on several parameters, such as number of candidates in discovery, preclinical and clinical phase of development, therapeutic area, amount raised through funding, number of investors, type of funding, number of deals signed, and number of patents filed.

One of the key objectives of the report was to estimate the future growth potential of CRISPR based therapeutics market, over the coming decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the financial evolution of the market for the period 2021-2030. For this purpose, we have segmented the future opportunity across [A] target therapeutic area (hematological disorders, oncological disorders, ophthalmic diseases, infectious diseases and others) [B] approach of therapy (ex vivo and in vivo) , [C] type of therapy (CAR-T cell therapy, HSC therapy, T cell therapy, and TIL) , [D] key geographical regions (North America, Europe and Asia-Pacific) . To account for uncertainties and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the anticipated industry's growth.

Key Questions Answered:

  • Who are the leading players engaged in the development of CRISPR based therapeutics?
  • Which key clinical conditions can be treated by CRISPR based drugs?
  • What are the investment trends in this industry?
  • Which partnership models are commonly adopted by stakeholders engaged in this domain?
  • How has the intellectual property landscape in this market evolved over the years?
  • Which factors are likely to influence the evolution of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Chapter Outlines:

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the CRISPR therapeutics market and its likely evolution in the short-mid to long term.

Chapter 3 provides a general introduction to CRISPR/Cas system. In addition, we have briefly described the components of CRISPR/Cas system, its mechanism of action and vehicles to deliver CRISPR/Cas components in to the target cells. The chapter lays emphasis on the applications of CRISPR technology. It also includes a discussion on the challenges associated with the use of CRISPR based therapeutics.

Chapter 4 presents a detailed assessment of the current market landscape of CRISPR based therapeutics, along with information on type of therapy (CAR-T therapy, HSC therapy, T cell therapy, Phage therapy and others), approach of therapy (in vivo and ex vivo), cell source (autologous and allogeneic), phase of development (discovery, preclinical and clinical), type of delivery vehicle used (viral vector, electroporation, LNPs, bacteriophage and others), target disease indication and therapeutic area (autoimmune disorders, cardiovascular diseases, dermatological disorders, genetic disorders, hematological disorders, immunological disorders, infectious diseases, inflammatory disorders, metabolic disorders, muscular diseases, neurological disorders, oncological disorders, ophthalmic diseases and others). In addition, it provides an overview of the CRISPR based therapeutics developer landscape, highlighting the players that are active in this domain. It includes information on their year of establishment, company size (in terms of number of employees) and location of headquarters of the drug developers. We have presented a logo landscape, highlighting the distribution of the drug developers based on company size and location of headquarters. Further, it presents an analysis on the initiatives of the big pharma companies in this domain.

Chapter 5 includes profiles of the key players engaged in the development of CRISPR based therapeutics (shortlisted based on strength of product portfolio). Each profile features a brief overview of the company, its financial information (if available), brief details of gene editing technology, therapeutic pipeline, recent developments and an informed future outlook.

Chapter 6 provides an in-depth analysis of the patents filed / granted for CRISPR technology since 2015. The analysis also highlights the key trends associated with these patents, including type of patent (granted patent, patent application and others), publication year, application year, geographical location / patent jurisdiction (North America, Europe, Asia-Pacific and Rest of the World), IPCR symbols, key inventors and leading industry / non-industry players. In addition, it includes a detailed patent benchmarking analysis of leading players and patent valuation analysis, which evaluates the qualitative and quantitative aspects of these patents.

Chapter 7 features a detailed analysis of the partnerships and collaborations that have been inked in this domain since 2014, covering research and licensing agreements, R&D agreements, licensing agreements, licensing and manufacturing agreement, product development and manufacturing agreements, joint ventures and other types of partnership deals. The chapter includes analysis based on year of partnership, type of partnership model, purpose of licensing deal, and most active player(s) (in terms of number of partnerships inked) . In addition, the chapter features a discussion on the surrogate licensing practice in the CRISPR based therapeutics market.

Chapter 8 provides an analysis of the investments made since 2014 at various stages of development of companies engaged in this domain, based on the year of investment, number of funding instances, amount invested and type of funding, highlighting most active players (in terms of number of funding instances and amount raised) and most active investors (in terms of number of funding instances) .

Chapter 9 presents an analysis of the start-ups (established after 2012 and having less than 200 employees) engaged in the development of CRISPR based therapeutics based on the parameters, such as number of candidates in discovery, preclinical and clinical phase of development, target therapeutic area, amount raised through funding, number of investors, type of funding, number of deals signed, and number of patents filed.

Chapter 10 features an elaborate discussion on the future market potential of various CRISPR based therapeutics. The chapter provides insights on the likely distribution of the current and forecasted opportunity across [A] target therapeutic area (hematological disorders, oncological disorders, ophthalmic diseases, infectious diseases and others) [B] approach of therapy (ex vivo and in vivo), [C] type of therapy (CAR-T cell therapy, HSC therapy, T cell therapy, and TIL) and [D] key geographical regions (North America, Europe and Asia-Pacific) .

Chapter 11 is a summary of the overall report, highlighting the key facts and figures related to the research and analysis presented in the previous chapters.

Chapter 12 is a collection of interview transcripts of discussions held with representatives of renowned organizations engaged in the CRISPR technology domain. In this chapter, we have presented the insights on our conversation with Harrison Wong (Public Relations, Burns McClellan, for eGenesis).

Chapter 13 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 14 is an appendix, which consists the list of companies and organizations mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. CRISPR/Cas System
    • 3.2.1. Mechanism of Action
    • 3.2.2. Innovations in CRISPR/Cas based Gene Editing
  • 3.4. CRISPR/Cas Component Delivery Vehicles
    • 3.4.1. Physical Delivery
    • 3.4.2. Viral Delivery
    • 3.4.3. Non-Viral Delivery
  • 3.5. Applications of the CRISPR/Cas System
  • 3.6. CRISPR/Cas based Therapeutics
  • 3.7. Challenges and Future Prospects

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. CRISPR/Cas based Therapeutics: Clinical Pipeline
    • 4.2.1. Analysis by Therapeutic Approach (In vivo / Ex vivo)
    • 4.2.2. Analysis by Cell Source
    • 4.2.3. Analysis by Cell Type
    • 4.2.4. Analysis by Target Gene
    • 4.2.5. Analysis by Delivery Vehicle Used
  • 4.3. CRISPR/Cas based Therapeutics: Registered Clinical Trials
    • 4.3.1. Analysis by Trial Phase
    • 4.3.2. Analysis by Therapeutic Area
    • 4.3.3. CRISPR/Cas based Therapeutics Clinical Trials: Analysis by Target Gene and Therapeutic Area
    • 4.3.4. Analysis by Gene Editing Approach
    • 4.3.5. Most Active Players: Analysis by Number of Trials
  • 4.4. CRISPR Based Therapeutics: Discovery and Preclinical Pipeline
    • 4.4.1. Analysis by Phase of Development
    • 4.4.2. Analysis by Therapeutic Area
    • 4.4.3. Analysis by Technology Used
    • 4.4.4. Analysis by Therapeutic Approach (In vivo/Ex vivo)
    • 4.4.5. Analysis by Delivery Vehicle Used
    • 4.4.6. Most Active Players: Analysis by Number of Drugs
  • 4.5. CRISPR/Cas based Therapeutics: Developer Landscape
    • 4.5.1. Analysis by Year of Establishment
    • 4.5.2. Analysis by Company Size
    • 4.5.3. Analysis by Geographical Location
    • 4.5.4. Logo Landscape: Analysis by Size and Phase of Development of CRISPR based Therapeutics
    • 4.5.5. Initiatives of Big Pharma Players

5. COMPANY PROFILES

  • 5.1. Chapter Overview
  • 5.2. CRISPR Therapeutics
    • 5.2.1. Company Overview
    • 5.2.2. Technology Overview
    • 5.2.3. CRISPR Therapeutics: Product Pipeline
    • 5.2.4. Recent Developments and Future Outlook
  • 5.3. Editas Medicine
    • 5.3.1. Company Overview
    • 5.3.2. Technology Overview
    • 5.3.3. Editas Medicine: Product Pipeline
    • 5.3.4. Recent Developments and Future Outlook
  • 5.4. Intellia Therapeutics
    • 5.4.1. Company Overview
    • 5.4.2. Technology Overview
    • 5.4.3. Intellia Therapeutics: Product Pipeline
    • 5.4.4. Recent Developments and Future Outlook
  • 5.5. Excision BioTherapeutics
    • 5.5.1. Company Overview
    • 5.5.2. Technology Overview
    • 5.5.3. Excision BioTherapeutics: Product Pipeline
    • 5.5.4. Recent Developments and Future Outlook
  • 5.6. Locus Biosciences
    • 5.6.1. Company Overview
    • 5.6.2. Technology Overview
    • 5.6.3. Locus Biosciences: Product Pipeline
    • 5.6.4. Recent Developments and Future Outlook
  • 5.7. Graphite Bio
    • 5.7.1. Company Overview
    • 5.7.2. Technology Overview
    • 5.7.3. Graphite Bio: Product Pipeline
    • 5.7.4. Recent Developments and Future Outlook
  • 5.8. Emendo Biotherapeutics (A Subsidiary of AnGes)
    • 5.8.1. Company Overview
    • 5.8.2. Technology Overview
    • 5.8.3. Emendo Biotherapeutics: Product Pipeline
    • 5.8.4. Recent Developments and Future Outlook
  • 5.9. Beam Therapeutics
    • 5.9.1. Company Overview
    • 5.9.2. Technology Overview
    • 5.9.3. Beam Therapeutics: Product Pipeline
    • 5.9.4. Recent Developments and Future Outlook
  • 5.10. Modalis Therapeutics
    • 5.10.1. Company Overview
    • 5.10.2. Technology Overview
    • 5.10.3. Modalis Therapeutics: Product Pipeline
    • 5.10.4. Recent Developments and Future Outlook
  • 5.11. Refuge Biotechnologies
    • 5.11.1. Company Overview
    • 5.11.2. Technology Overview
    • 5.11.3. Refuge Biotechnologies: Product Pipeline
    • 5.11.4. Recent Developments and Future Outlook

6. PATENT ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Scope and Methodology
  • 6.3. CRISPR/Cas Gene Editing Technology: Patent Analysis
    • 6.3.1. Analysis by Publication Year and Patent Type, Pre-2015-2020
    • 6.3.2. Analysis by Patent Application Area
    • 6.3.3. Analysis by Patent Issuing Authority
    • 6.3.4. Analysis by Geographical Location
    • 6.3.5. Analysis by IPCR Symbols
    • 6.3.6. Analysis by Type of Organization
    • 6.3.7. Leading Players: Analysis by Number of Patents
  • 6.4. CRISPR/Cas Gene Editing Technology: Patent Benchmarking
    • 6.4.1. Analysis by Patent Characteristics
  • 6.5. CRISPR/Cas Gene Editing Technology: Patent Valuation Analysis
  • 6.6. Popular Patents: Analysis by Number of Citations

7. PARTNERSHIPS AND COLLABORATIONS

  • 7.1. Chapter Overview
  • 7.2. Partnership Models
  • 7.3. CRISPR Licensing Landscape: Surrogate Licensing
  • 7.4. CRISPR/Cas based Therapeutics: Recent Partnerships
    • 7.4.1. Analysis by Year of Partnership
    • 7.4.2. Analysis by Type of Partnership
    • 7.4.3. Analysis by Purpose of Licensing
    • 7.4.4. Most Active Players: Analysis by Number of Partnerships

8. FUNDING AND INVESTMENT ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Types of Funding Instances
  • 8.3. CRISPR/Cas based Therapeutics and Affiliated Technologies: Recent Funding Instances
    • 8.3.1. Analysis by Year of Investment
    • 8.3.2. Analysis by Amount Invested
    • 8.3.3. Analysis by Type of Funding
    • 8.3.4. Most Active Players: Analysis by Number of Funding Instances
    • 8.3.5. Most Active Investors: Analysis by Number of Funding Instances
  • 8.4. Concluding Remarks

9. START-UP HEALTH INDEXING

  • 9.1. Chapter Overview
  • 9.2. Start-ups Focused on CRISPR/Cas based Therapeutics
    • 9.3.1. Analysis by Location of Headquarters
  • 9.4 Benchmarking of Start-ups
    • 9.4.1. Analysis by Portfolio Strength
    • 9.4.2. Analysis by Pipeline Maturity
    • 9.4.3. Analysis by Therapeutic Diversity
    • 9.4.4. Analysis by Capital Accrued through Investments
    • 9.4.5. Analysis by Number of Investors
    • 9.4.6. Analysis of Partnership Activity
    • 9.4.7. Analysis of Patent Portfolio
    • 9.4.8. Start-ups Health Indexing: Roots Analysis Perspective

10. MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Limitations
  • 10.3. Key Assumptions and Forecast Methodology
  • 10.4. Overall CRISPR/Cas based Therapeutics Market, 2021-2030
  • 10.5. CRISPR/Cas based Therapeutics Market, 2021-2030: Distribution by Type of Therapy
  • 10.6. CRISPR/Cas based Therapeutics Market, 2021-2030: Distribution by Therapeutic Approach
  • 10.7. CRISPR/Cas based Therapeutics Market, 2021-2030: Distribution by Therapeutic Area
  • 10.8. CRISPR/Cas based Therapeutics Market, 2021-2030: Distribution by Geographical Region
  • 10.9. Product-wise Sales Forecast
    • 10.9.1. EDIT-101 (Editas Medicine)
      • 10.9.1.1. Target Patient Population
      • 10.9.1.2. Sales Forecast (USD Million)
    • 10.9.2. OTQ923 / HIX763 (Intellia Therapeutics / Novartis)
      • 10.9.2.1. Target Patient Population
      • 10.9.2.2. Sales Forecast (USD Million)
    • 10.9.3. CTX001 for Sickle Cell (CRISPR Therapeutics)
      • 10.9.3.1. Target Patient Population
      • 10.9.3.2. Sales Forecast (USD Million)
    • 10.9.4. CTX001 for Transfusion-Dependent Beta Thalassemia (CRISPR Therapeutics)
      • 10.9.4.1. Target Patient Population
      • 10.9.4.2. Sales Forecast (USD Million)
    • 10.9.5. Unnamed Drug for Metastatic Gastrointestinal Epithelial Cancer (Intima Bioscience)
      • 10.9.5.1. Target Patient Population
      • 10.9.5.2. Sales Forecast (USD Million)
    • 10.9.6. BD111 (Shanghai BD Gene Therapeutics)
      • 10.9.6.1. Target Patient Population
      • 10.9.6.2. Sales Forecast (USD Million)
    • 10.9.7. Unnamed Drug for Beta Thalassemia Major (Shanghai Bioray Laboratories)
      • 10.9.7.1. Target Patient Population
      • 10.9.7.2. Sales Forecast (USD Million)
    • 10.9.8. CD19-UCART (Shanghai Bioray Laboratories)
      • 10.9.8.1. Target Patient Population
      • 10.9.8.2. Sales Forecast (USD Million)
    • 10.9.9. Unnamed Drug for Advanced Non-Small Cell Lung Cancer (Guangzhou Anjie Biomedical Technology)
      • 10.9.9.1. Target Patient Population
      • 10.9.9.2. Sales Forecast (USD Million)
    • 10.9.10. Unnamed Drug for Advanced Prostate Cancer (Guangzhou Anjie Biomedical Technology)
      • 10.9.10.1. Target Patient Population
      • 10.9.10.2. Sales Forecast (USD Million)

11. EXECUTIVE INSIGHTS

  • 11.1 Chapter Overview
  • 11.2 eGenesis
    • 11.2.1. Company Snapshot
    • 11.2.2. Interview Transcript: Harisson Wong (Public Relations, Burns McClellan, for eGenesis

12. CONCLUDING REMARKS

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1 Structure of CRISPR/Cas
  • Figure 3.2 DNA Repair Mechanism Used in CRISPR/Cas System
  • Figure 3.3 CRISPR/Cas System: Mechanism of Action
  • Figure 3.4 Applications of CRISPR/Cas System
  • Figure 4.1 CRISPR/Cas based Therapeutics Clinical Pipeline: Distribution by Therapeutic Approach (In vivo / Ex vivo)
  • Figure 4.2 CRISPR/Cas based Therapeutics Clinical Pipeline: Distribution by Cell Source
  • Figure 4.3 CRISPR/Cas based Therapeutics Clinical Pipeline: Distribution by Cell Type
  • Figure 4.4 CRISPR/Cas based Therapeutics Clinical Pipeline: Distribution by Cell Source and Cell Type
  • Figure 4.5 CRISPR/Cas based Therapeutics Clinical Pipeline: Distribution by Target Gene
  • Figure 4.6 CRISPR/Cas based Therapeutics Clinical Pipeline: Distribution by Delivery Vehicle Used and Therapeutic Approach
  • Figure 4.7 CRISPR/Cas based Therapeutics Clinical Trials: Distribution by Trial Phase
  • Figure 4.8 CRISPR/Cas based Therapeutics Clinical Trials: Distribution by Therapeutic Area
  • Figure 4.9 CRISPR/Cas based Therapeutics Clinical Trials: Distribution by Target Gene and Therapeutic Area
  • Figure 4.10 CRISPR/Cas based Therapeutics Clinical Trials: Distribution by Gene Editing Approach
  • Figure 4.11 Most Active Players: Distribution by Number of trials
  • Figure 4.12 CRISPR/Cas based Therapeutics Discovery and Preclinical Pipeline: Distribution by Phase of Development
  • Figure 4.13 CRISPR/Cas based Therapeutics Discovery and Preclinical Pipeline: Distribution by Therapeutic Area
  • Figure 4.14 CRISPR/Cas based Therapeutics Discovery and Preclinical Pipeline: Distribution by Technology Used
  • Figure 4.15 CRISPR/Cas based Therapeutics Discovery and Preclinical Pipeline: Distribution by Therapeutic Approach (In vivo/Ex vivo)
  • Figure 4.16 CRISPR/Cas based Therapeutics Discovery and Preclinical Pipeline: Distribution by Delivery Vehicle Used
  • Figure 4.17 Most Active Players: Distribution by Number of Drugs
  • Figure 4.18 CRISPR based Therapeutics Developers: Distribution by Year of Establishment
  • Figure 4.19 CRISPR/Cas based Therapeutics Developers: Distribution by Company Size
  • Figure 4.20 CRISPR/Cas based Therapeutics Developers: Distribution by Geographical Location
  • Figure 4.21 CRISPR/Cas based Therapeutics Developers: Logo Landscape
  • Figure 6.1 Patent Analysis: Distribution by Patent Type
  • Figure 6.2 Patent Analysis: Cumulative Distribution by Publication Year, Pre 2015-2020
  • Figure 6.3 Patent Analysis: Distribution by Publication Year and Patent Type, Pre-2015-2020
  • Figure 6.4 Patent Analysis: Distribution by Patent Application Area
  • Figure 6.5 Patent Analysis: Distribution by Patent Issuing Authority
  • Figure 6.6 Patent Analysis: Distribution by Geographical Location
  • Figure 6.7 Patent Analysis: Distribution by IPCR Symbols
  • Figure 6.8 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
  • Figure 6.9 Patent Analysis: Leading Industry Players
  • Figure 6.10 Patent Analysis: Leading Non-Industry Players
  • Figure 6.11 Patent Analysis: Patent Assignees
  • Figure 6.12 Patent Analysis (Leading Players): Benchmarking by Patent Characteristics (IPCR Symbols)
  • Figure 6.13 Patent Analysis: Distribution of Patents by Age (2001-2020)
  • Figure 6.14 CRISPR/Cas Gene Editing Technology: Patent Valuation
  • Figure 7.1 CRISPR Licensing Landscape: Surrogate Licensing
  • Figure 7.2 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2021 (till February)
  • Figure 7.3 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 7.4 Partnerships and Collaborations: Year-wise Trend by Type of Partnership, 2015-2021 (till February)
  • Figure 7.5 Licensing Agreements: Distribution by Type of Licensing
  • Figure 7.6 Licensing Agreements: Distribution by Purpose of Licensing
  • Figure 7.7 Most Active Players: Distribution by Number of Partnerships
  • Figure 8.1 CRISPR/Cas based Therapeutics and Affiliated Technologies: List of Funding Instances, 2014-2021 (till February)
  • Figure 8.2 Funding and Investments: Cumulative Amount Invested by Year, 2014-2021 (till February) (USD Million)
  • Figure 8.3 Funding and Investments: Distribution by Type of Funding
  • Figure 8.4 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
  • Figure 8.5 Funding Instances: Year-wise Trend of Amount Invested, 2014-2021 (till February) (USD Million)
  • Figure 8.6 Funding and Investments: Summary of Investments, 2014-2021 (till February) (USD Million)
  • Figure 8.7 Most Active Players: Distribution by Number of Funding Instances
  • Figure 8.8 Most Active Players: Distribution by Amount Raised (USD Million)
  • Figure 8.9 Most Active Investors: Distribution by Number of Funding Instances
  • Figure 8.10 Summary of Investments
  • Figure 9.1 Start-ups focused on CRISPR/Cas based Therapeutics: Distribution by Location of Headquarters
  • Figure 9.2 Benchmarking of Start-ups: Distribution by Portfolio Strength
  • Figure 9.3 Benchmarking of Start-ups: Distribution by Pipeline Maturity
  • Figure 9.4 Benchmarking of Start-ups: Mapping by Year of Establishment and Clinical Development
  • Figure 9.5 Benchmarking of Start-ups: Distribution by Therapeutic Diversity
  • Figure 9.6 Benchmarking of Start-ups: Distribution by Capital Accrued through Investments (USD Million)
  • Figure 9.7 Benchmarking of Start-ups: Distribution by Number of Investors
  • Figure 9.8 Benchmarking of Start-ups: Distribution by Partnership Activity
  • Figure 9.9 Benchmarking of Start-ups: Distribution by Patent Portfolio
  • Figure 9.10 Start-up Health Indexing: Roots Analysis Perspective
  • Figure 9.11 Start-up Health Indexing: Leading Companies
  • Figure 10.1 Global CRISPR/Cas based Therapeutics Market, 2021-2030 (USD Million)
  • Figure 10.2 CRISPR/Cas based Therapeutics Market, 2021-2030: Distribution by Type of Therapy (USD Million)
  • Figure 10.3 CRISPR/Cas based Therapeutics Market, 2021-2030: Distribution by Therapeutic Approach (USD Million)
  • Figure 10.4 CRISPR/Cas based Therapeutics Market, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Figure 10.5 CRISPR/Cas based Therapeutics Market, 2021-2030: Distribution by Geographical Region (USD Million)
  • Figure 10.6 EDIT-101 Target Patient Population (Till 2030)
  • Figure 10.7 EDIT-101 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.8 OTQ923 / HIX763 Target Patient Population (Till 2030)
  • Figure 10.9 OTQ923 / HIX763 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.10 CTX001 for Sickle Cell Disease Target Patient Population (Till 2030)
  • Figure 10.11 CTX001 for Sickle Cell Disease Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.12 CTX001 for Transfusion-Dependent β-Thalassemia Target Patient Population (Till 2030)
  • Figure 10.13 CTX001 for Transfusion-Dependent β-Thalassemia Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.14 Unnamed Drug for Metastatic Gastrointestinal Epithelial Cancer Target Patient Population (Till 2030)
  • Figure 10.15 Unnamed Drug for Metastatic Gastrointestinal Epithelial Cancer Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.16 BD111 Target Patient Population (Till 2030)
  • Figure 10.17 BD111 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.18 Unnamed Drug for Beta Thalassemia Major Target Patient Population (Till 2030)
  • Figure 10.19 Unnamed Drug for Beta Thalassemia Major Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.20 CD19-UCART Target Patient Population (Till 2030)
  • Figure 10.21 CD19-UCART Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.22 Unnamed Drug for Advanced Non-Small Cell Lung Cancer Target Patient Population (Till 2030)
  • Figure 10.23 Unnamed Drug for Advanced Non-Small Cell Lung Cancer Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.24 Unnamed Drug for Advanced Prostate Cancer Target Patient Population (Till 2030)
  • Figure 10.25 Unnamed Drug for Advanced Prostate Cancer Sales Forecast (Till 2030): Base Scenario (USD Million)

List Of Tables

  • Table 4.1 CRISPR/Cas based Therapeutics: Clinical Pipeline
  • Table 4.2 CRISPR/Cas based Therapeutics: Registered Clinical Trials
  • Table 4.3 CRISPR/Cas based Therapeutics: Discovery and Preclinical Pipeline
  • Table 4.4 CRISPR/Cas based Therapeutics: List of Developers
  • Table 4.5 Big Pharma Initiatives
  • Table 5.1 CRISPR/Cas based Therapeutics: List of Companies Profiled
  • Table 5.2 CRISPR Therapeutics: Company Snapshot
  • Table 5.3 CRISPR Therapeutics: Product Pipeline
  • Table 5.4 CRISPR Therapeutics: Recent Developments and Future Outlook
  • Table 5.5 Editas Medicine: Company Snapshot
  • Table 5.6 Editas Medicine: Product Pipeline
  • Table 5.7 Editas Medicine: Recent Developments and Future Outlook
  • Table 5.8 Intellia Therapeutics: Company Snapshot
  • Table 5.9 Intellia Therapeutics: Product Pipeline
  • Table 5.10 Intellia Therapeutics: Recent Developments and Future Outlook
  • Table 5.11 Excision BioTherapeutics: Company Snapshot
  • Table 5.12 Excision BioTherapeutics: Product Pipeline
  • Table 5.13 Excision BioTherapeutics: Recent Developments and Future Outlook
  • Table 5.14 Locus Biosciences: Company Snapshot
  • Table 5.15 Locus Biosciences: Product Pipeline
  • Table 5.16 Locus Biosciences: Recent Developments and Future Outlook
  • Table 5.17 Graphite Bio: Company Snapshot
  • Table 5.18 Graphite Bio: Product Pipeline
  • Table 5.19 Graphite Bio: Recent Developments and Future Outlook
  • Table 5.20 Emendo Biotherapeutics: Company Snapshot
  • Table 5.21 Emendo Biotherapeutics: Product Pipeline
  • Table 5.22 Emendo Biotherapeutics: Recent Developments and Future Outlook
  • Table 5.23 Beam Therapeutics: Company Snapshot
  • Table 5.24 Beam Therapeutics: Product Pipeline
  • Table 5.25 Beam Therapeutics: Recent Developments and Future Outlook
  • Table 5.26 Modalis Therapeutics: Company Snapshot
  • Table 5.27 Modalis Therapeutics: Product Pipeline
  • Table 5.28 Modalis Therapeutics: Recent Developments and Future Outlook
  • Table 5.29 Refuge Biotechnologies: Company Snapshot
  • Table 5.30 Refuge Biotechnologies: Product Pipeline
  • Table 5.31 Refuge Biotechnologies: Recent Developments and Future Outlook
  • Table 6.1 Patent Analysis: IPCR Class Symbol Definitions
  • Table 6.2 Patent Analysis: IPCR Symbol Definitions
  • Table 6.3 Patent Analysis: IPCR Classification Symbol Definitions
  • Table 6.4 Patent Analysis: Summary of Benchmarking Analysis
  • Table 6.5 Patent Analysis: Categorization based on Weighted Valuation Scores
  • Table 6.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
  • Table 6.7 Patent Portfolio: List of Popular Patents (by Number of Citations)
  • Table 7.1 CRISPR/Cas based Therapeutics: List of Partnerships, 2015-2021 (till February)
  • Table 7.2 Most Active Players: Distribution by Number of Partnerships
  • Table 8.1 CRISPR/Cas based Therapeutics and Affiliated Technologies: List of Funding Instances, 2014-2021 (till February)
  • Table 8.2 Funding and Investments: Summary of Investments
  • Table 9.1 CRISPR/Cas Based Therapeutics Start-ups: Distribution by Location of Headquarters
  • Table 10.1 CRISPR/Cas based Therapeutics: Expected Launch Years of Advanced Stage Drug Candidates
  • Table 13.1 CRISPR/Cas based Therapeutics Clinical Pipeline: Distribution by Therapeutic Approach (In vivo / Ex vivo)
  • Table 13.2 CRISPR/Cas based Therapeutics Clinical Pipeline: Distribution by Cell Source
  • Table 13.3 CRISPR/Cas based Therapeutics Clinical Pipeline: Distribution by Cell Type
  • Table 13.4 CRISPR/Cas based Therapeutics Clinical Pipeline: Distribution by Cell Source and Cell Type
  • Table 13.5 CRISPR/Cas based Therapeutics Clinical Pipeline: Distribution by Target Gene
  • Table 13.6 CRISPR/Cas based Therapeutics Clinical Pipeline: Distribution by Delivery Vehicle Used and Therapeutic Approach
  • Table 13.7 CRISPR/Cas based Therapeutics Clinical Trials: Distribution by Phase of Development
  • Table 13.8 CRISPR/Cas based Therapeutics Clinical Trials: Distribution by Therapeutic Area
  • Table 13.9 CRISPR/Cas based Therapeutics Clinical Trials: Distribution by Gene Editing Approach
  • Table 13.10 Most Active Players: Distribution by Number of trials
  • Table 13.11 CRISPR/Cas based Therapeutics Discovery and Preclinical Pipeline: Distribution by Phase of Development
  • Table 13.12 CRISPR/Cas based Therapeutics Discovery and Preclinical Pipeline: Distribution by Therapeutic Area
  • Table 13.13 CRISPR/Cas based Therapeutics Discovery and Preclinical Pipeline: Distribution by Technology Used
  • Table 13.14 CRISPR/Cas based Therapeutics Discovery and Preclinical Pipeline: Distribution by Therapeutic Approach (In vivo / Ex vivo)
  • Table 13.15 CRISPR/Cas based Therapeutics Discovery and Preclinical Pipeline: Distribution by Delivery Vehicle Used
  • Table 13.16 Most Active Players: Distribution by Number of Drugs
  • Table 13.17 CRISPR/Cas based Therapeutics Developers: Distribution by Year of Establishment
  • Table 13.18 CRISPR/Cas based Therapeutics Developers: Distribution by Company Size
  • Table 13.19 CRISPR/Cas based Therapeutics Developers: Distribution by Geographical Location
  • Table 13.20 Patent Analysis: Distribution by Patent Type
  • Table 13.21 Patent Analysis: Cumulative Distribution by Publication Year, Pre-2015-2020
  • Table 13.22 Patent Analysis: Distribution by Publication Year and Patent Type, Pre-2015-2020
  • Table 13.23 Patent Analysis: Distribution by Patent Application Area
  • Table 13.24 Patent Analysis: Distribution by Patent Issuing Authority
  • Table 13.25 Patent Analysis: Distribution by Geographical Location
  • Table 13.26 Patent Analysis: Cumulative Year-wise Distribution by Type of Organization
  • Table 13.27 Patent Analysis: Leading Industry Players
  • Table 13.28 Patent Analysis: Leading Non-Industry Players
  • Table 13.29 Patent Analysis: Patent Assignees
  • Table 13.30 Patent Analysis: Distribution of Patents by Age (2001-2020)
  • Table 13.31 Partnerships and Collaborations: Cumulative Year-wise Trend, 2015-2021 (till February)
  • Table 13.32 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 13.33 Partnerships and Collaborations: Year-wise Trend by Type of Partnership, 2015-2021 (till February)
  • Table 13.34 Licensing Agreements: Distribution by Type of Licensing
  • Table 13.35 Licensing Agreements: Distribution by Purpose of Licensing
  • Table 13.36 Most Active Players: Distribution by Number of Partnerships
  • Table 13.37 CRISPR/Cas based Therapeutics and Affiliated Technologies: List of Funding Instances, 2014-2021 (till February)
  • Table 13.38 Funding and Investments: Cumulative Amount Invested by Year, 2014-2021 (till February) (USD Million)
  • Table 13.39 Funding and Investments: Distribution of by Type of Funding
  • Table 13.40 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
  • Table 13.41 Most Active Players: Distribution by Number of Funding Instances
  • Table 13.42 Most Active Players: Distribution by Amount Raised (USD Million)
  • Table 13.43 Most Active Investors: Distribution by Number of Funding Instances
  • Table 13.44 Start-ups focused on CRISPR/Cas based Therapeutics: Distribution by Location of Headquarters
  • Table 13.45 Benchmarking of Start-ups: Distribution by Portfolio Strength
  • Table 13.46 Benchmarking of Start-ups: Distribution by Pipeline Drugs by Stage of Development
  • Table 13.47 Benchmarking of Start-ups: Distribution by Therapeutic Area
  • Table 13.48 Benchmarking of Start-ups: Distribution by Capital Accrued through Investments (USD Million)
  • Table 13.49 Benchmarking of Start-ups: Distribution by Number of Investors
  • Table 13.50 Benchmarking of Start-ups: Distribution by Partnership Activity
  • Table 13.51 Benchmarking of Start-ups: Distribution by Patent Portfolio
  • Table 13.52 Global CRISPR/Cas based Therapeutics Market, 2021-2030 (USD Million)
  • Table 13.53 CRISPR/Cas based Therapeutics Market, 2021-2030: Distribution by Type of Therapy (USD Million)
  • Table 13.54 CRISPR/Cas based Therapeutics Market, 2021-2030: Distribution by Therapeutic Approach (USD Million)
  • Table 13.55 CRISPR/Cas based Therapeutics Market, 2021-2030: Distribution by Therapeutic Area (USD Million)
  • Table 13.56 CRISPR/Cas based Therapeutics Market, 2021-2030: Distribution by Geographical Region (USD Million)
  • Table 13.57 EDIT-101 Target Patient Population (Till 2030)
  • Table 13.58 EDIT-101 Sales Forecast (Till 2030) (USD Million)
  • Table 13.59 OTQ923 / HIX763 Target Patient Population (Till 2030)
  • Table 13.60 OTQ923 / HIX763 Sales Forecast (Till 2030) (USD Million)
  • Table 13.61 CTX001 for Sickle Cell Disease Target Patient Population (Till 2030)
  • Table 13.62 CTX001 for Sickle Cell Disease Sales Forecast (Till 2030) (USD Million)
  • Table 13.63 CTX001 for Transfusion-Dependent β-Thalassemia Target Patient Population (Till 2030)
  • Table 13.64 CTX001 for Transfusion-Dependent β-Thalassemia Sales Forecast (Till 2030) (USD Million)
  • Table 13.65 Unnamed Drug for Metastatic Gastrointestinal Epithelial Cancer Target Patient Population (Till 2030)
  • Table 13.66 Unnamed Drug for Metastatic Gastrointestinal Epithelial Cancer Sales Forecast (Till 2030) (USD Million)
  • Table 13.67 BD111 Target Patient Population (Till 2030)
  • Table 13.68 BD111 Sales Forecast (Till 2030) (USD Million)
  • Table 13.69 Unnamed Drug for Beta Thalassemia Major Target Patient Population (Till 2030)
  • Table 13.70 Unnamed Drug for Beta Thalassemia Major Sales Forecast (Till 2030) (USD Million)
  • Table 13.71 CD19-UCART Target Patient Population (Till 2030)
  • Table 13.72 CD19-UCART Sales Forecast (Till 2030) (USD Million)
  • Table 13.73 Unnamed Drug for Advanced Non-Small Cell Lung Cancer Target Patient Population (Till 2030)
  • Table 13.74 Unnamed Drug for Advanced Non-Small Cell Lung Cancer Sales Forecast (Till 2030) (USD Million)
  • Table 13.75 Unnamed Drug for Advanced Prostate Cancer Target Patient Population (Till 2030)
  • Table 13.76 Unnamed Drug for Advanced Prostate Cancer Sales Forecast (Till 2030) (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report.

  • 1. AbbVie
  • 2. Adverum Biotechnologies
  • 3. Anagenesis Biotechnologies
  • 4. Asklepios BioPharmaceutical (acquired by Bayer)
  • 5. Astellas Pharma
  • 6. Batu Biologics
  • 7. Bayer
  • 8. Beam Therapeutics
  • 9. Beth Israel Deaconess Medical Center
  • 10. Biogen
  • 11. Biomedical Advanced Research and Development Authority (BARDA)
  • 12. BlueRock Therapeutics (acquired by Bayer)
  • 13. Bristol-Myers Squibb
  • 14. California Institute for Regenerative Medicine (CIRM)
  • 15. CARB-X
  • 16. Caribou Biosciences
  • 17. Caspr Biotech
  • 18. Catalent
  • 19. Celgene
  • 20. Cellectis
  • 21. Chengdu MedGenCell
  • 22. Columbia University
  • 23. CRISPR Therapeutics
  • 24. CureVac
  • 25. Cystic Fibrosis Foundation Therapeutics
  • 26. Duke University
  • 27. DuPont
  • 28. EdiGene
  • 29. Editas Medicine
  • 30. Eisai
  • 31. Eligo Bioscience
  • 32. EmendoBio (acquired by AnGes)
  • 33. Excision BioTherapeutics
  • 34. Eye & ENT Hospital of Fudan University
  • 35. Fate Therapeutics
  • 36. GEMoaB
  • 37. GenEdit
  • 38. Genevant Sciences
  • 39. GlaxoSmithKline
  • 40. Graphite Bio
  • 41. Guangzhou Anjie Biomedical Technology
  • 42. Harvard University
  • 43. ImmunoChina Pharmaceuticals
  • 44. Institute of Molecular and Clinical Ophthalmology Basel (IOB)
  • 45. Intellia Therapeutics
  • 46. Intima Bioscience
  • 47. J. David Gladstone Institutes
  • 48. Janssen Pharmaceuticals
  • 49. KSQ Therapeutics
  • 50. Locus Biosciences
  • 51. Mammoth Biosciences
  • 52. Masonic Cancer Center
  • 53. MaSTherCell
  • 54. MaxCyte
  • 55. Memorial Sloan Kettering Cancer Center
  • 56. Modalis Therapeutics (formerly known as EdiGENE)
  • 57. Mustang Bio
  • 58. Nanjing Bioheng Biotech
  • 59. National Institutes of Health
  • 60. Navega Therapeutics
  • 61. Nemesis Bioscience
  • 62. Neon Therapeutics
  • 63. Novartis
  • 64. Poseida Therapeutics
  • 65. Prime Medicine
  • 66. ProBioGen
  • 67. Refuge Biotechnologies
  • 68. Regeneron
  • 69. Sandhill Therapeutics
  • 70. Sarepta Therapeutics
  • 71. Scribe Therapeutics
  • 72. Seven Therapeutics
  • 73. Shanghai BD Gene Therapeutics
  • 74. Shanghai Bioray Laboratories
  • 75. Sherlock Biosciences
  • 76. Shionogi
  • 77. Sichuan University
  • 78. SNIPR Biome
  • 79. Spotlight Therapeutics
  • 80. StrideBio
  • 81. Takeda
  • 82. Temple University
  • 83. TeneoBio
  • 84. The First Affiliated Hospital of Guangdong Pharmaceutical University
  • 85. University of California
  • 86. University of Texas
  • 87. University of Washington
  • 88. Vertex Pharmaceuticals
  • 89. Verve Therapeutics
  • 90. ViaCyte
  • 91. Xijing Hospital
  • 92. Yufan Biotechnologies
  • 93. Zhejiang University